[go: up one dir, main page]

EA199900301A2 - Замещенные трициклические соединения - Google Patents

Замещенные трициклические соединения

Info

Publication number
EA199900301A2
EA199900301A2 EA199900301A EA199900301A EA199900301A2 EA 199900301 A2 EA199900301 A2 EA 199900301A2 EA 199900301 A EA199900301 A EA 199900301A EA 199900301 A EA199900301 A EA 199900301A EA 199900301 A2 EA199900301 A2 EA 199900301A2
Authority
EA
Eurasian Patent Office
Prior art keywords
tricyclic compounds
substituted tricyclic
compounds
substituted
cfla
Prior art date
Application number
EA199900301A
Other languages
English (en)
Other versions
EA199900301A3 (ru
EA002347B1 (ru
Inventor
Бенджамин Алан Андерсон
Николас Джеймс Бах
Жоли Анн Бастиан
Нэнси Кей Харн
Ричард Вальтц Харпер
Гари Алан Хайт
Майкл Дин Кинник
Хо-Шен Лин
Ричард Джеймс Лончарик
Джон МакНейлл МакДжилл III
Эдвард Дэвид Михелик
Джон Майкл мл. Морин
Майкл ЛеРой Филлипс
Майкл Энрико Ричетт
Дэниел Джон Солл
Джейсон Скотт Сойер
Ричард Вальтер Шевитц
Роберт Теодор Василефф
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900301A2 publication Critical patent/EA199900301A2/ru
Publication of EA199900301A3 publication Critical patent/EA199900301A3/ru
Publication of EA002347B1 publication Critical patent/EA002347B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описан класс новых трициклических соединений, а также применение таких соединений для ингибирования сФЛАопосредованного высвобождения жирных кислот для лечений состояний, таких как септический шок.
EA199900301A 1998-04-17 1999-04-16 Замещенные трициклические соединения EA002347B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (3)

Publication Number Publication Date
EA199900301A2 true EA199900301A2 (ru) 1999-10-28
EA199900301A3 EA199900301A3 (ru) 2000-04-24
EA002347B1 EA002347B1 (ru) 2002-04-25

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900301A EA002347B1 (ru) 1998-04-17 1999-04-16 Замещенные трициклические соединения
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола

Country Status (30)

Country Link
EP (2) EP0952149B1 (ru)
JP (2) JPH11322713A (ru)
KR (2) KR100586761B1 (ru)
CN (1) CN1149193C (ru)
AR (2) AR018593A1 (ru)
AT (2) ATE268756T1 (ru)
AU (2) AU753436B2 (ru)
BR (2) BR9902365A (ru)
CA (2) CA2269246C (ru)
CO (2) CO5011054A1 (ru)
CZ (2) CZ137099A3 (ru)
DE (2) DE69918590T2 (ru)
DK (1) DK0950657T3 (ru)
DZ (1) DZ2769A1 (ru)
EA (2) EA002347B1 (ru)
ES (2) ES2222663T3 (ru)
HU (2) HUP9901220A3 (ru)
ID (2) ID23287A (ru)
IL (2) IL129483A0 (ru)
NO (2) NO314400B1 (ru)
NZ (3) NZ335251A (ru)
PE (2) PE20000432A1 (ru)
PL (2) PL332565A1 (ru)
PT (1) PT950657E (ru)
SG (2) SG81977A1 (ru)
SI (1) SI0950657T1 (ru)
TR (2) TR199900843A2 (ru)
TW (1) TWI238160B (ru)
YU (2) YU19199A (ru)
ZA (2) ZA992772B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
AU2001267825A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
EP1300159B1 (en) * 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedies for cancer
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
ATE353876T1 (de) * 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
EP2256105B1 (en) 2008-03-26 2013-12-04 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
EP2282742A1 (en) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CN111362863A (zh) 2012-11-30 2020-07-03 通用电气健康护理有限公司 三环吲哚衍生物的结晶方法
WO2014083163A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
JP2001503055A (ja) * 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli TREATMENT OF ALZHEIMER DISEASE
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
NZ335253A (en) 2000-11-24
CN1149193C (zh) 2004-05-12
HUP9901220A3 (en) 2001-11-28
EA002816B1 (ru) 2002-10-31
NO991821D0 (no) 1999-04-16
EP0952149A3 (en) 2001-08-16
EP0950657B1 (en) 2004-07-14
EA199900303A2 (ru) 1999-10-28
HU9901221A (hu) 2000-04-28
EP0952149B1 (en) 2004-06-09
EA199900301A3 (ru) 2000-04-24
PE20000476A1 (es) 2000-06-02
CA2269246C (en) 2009-08-25
IL129485A0 (en) 2000-02-29
YU19199A (sh) 2002-08-12
PL332566A1 (en) 1999-10-25
PT950657E (pt) 2004-11-30
NO991822L (no) 1999-10-18
YU18999A (sh) 2002-08-12
NO314400B1 (no) 2003-03-17
SI0950657T1 (en) 2005-02-28
DE69917833D1 (de) 2004-07-15
KR19990083232A (ko) 1999-11-25
NO991822D0 (no) 1999-04-16
HU9901221D0 (en) 1999-06-28
ATE268756T1 (de) 2004-06-15
EP0950657A3 (en) 2001-08-16
ID23761A (id) 2000-05-11
PL332565A1 (en) 1999-10-25
ZA992772B (en) 2002-07-16
JPH11322713A (ja) 1999-11-24
CO5011054A1 (es) 2001-02-28
HUP9901221A3 (en) 2001-11-28
JP2000026416A (ja) 2000-01-25
BR9901279A (pt) 2000-05-02
EA199900303A3 (ru) 2000-04-24
DK0950657T3 (da) 2004-11-22
CZ137099A3 (cs) 1999-11-17
AU753547B2 (en) 2002-10-24
NO312240B1 (no) 2002-04-15
SG81977A1 (en) 2001-07-24
SG81976A1 (en) 2001-07-24
ZA992771B (en) 2002-04-18
KR19990083233A (ko) 1999-11-25
AU2381799A (en) 1999-10-28
TR199900843A2 (xx) 2000-02-21
CZ136999A3 (cs) 1999-11-17
NO991821L (no) 1999-10-18
HU9901220D0 (en) 1999-06-28
AR018186A1 (es) 2001-10-31
DE69917833T2 (de) 2005-07-14
CA2269246A1 (en) 1999-10-17
DZ2769A1 (fr) 2003-12-01
PE20000432A1 (es) 2000-05-23
EP0950657A2 (en) 1999-10-20
EP0952149A2 (en) 1999-10-27
ID23287A (id) 2000-04-05
HU9901220A (hu) 2000-04-28
CO5031247A1 (es) 2001-04-27
DE69918590D1 (de) 2004-08-19
NZ507564A (en) 2002-10-25
TWI238160B (en) 2005-08-21
KR100586761B1 (ko) 2006-06-08
ATE271037T1 (de) 2004-07-15
BR9902365A (pt) 2001-04-24
JP4435330B2 (ja) 2010-03-17
TR199900853A3 (tr) 1999-11-22
IL129483A0 (en) 2000-02-29
NZ335251A (en) 2000-11-24
AU2381999A (en) 1999-10-28
AU753436B2 (en) 2002-10-17
ES2222663T3 (es) 2005-02-01
AR018593A1 (es) 2001-11-28
TR199900853A2 (xx) 1999-11-22
CN1253948A (zh) 2000-05-24
ES2226286T3 (es) 2005-03-16
CA2269262A1 (en) 1999-10-17
EA002347B1 (ru) 2002-04-25
DE69918590T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
EA199900301A2 (ru) Замещенные трициклические соединения
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
EA199900304A2 (ru) Замещенные трициклические соединения
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
YU19299A (sh) Supstituisani tricikli
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
IL130338A0 (en) Pyrroles as sPLA2 inhibitors
KR970704695A (ko) 인돌리진 sPLA₂억제제(INDOLIZINE sPLA₂INHIBITORS)
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
DE69720034D1 (de) PHENYLGLYOXAMIDE ALS sPLA2-INHIBITOREN
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
DE69910432D1 (de) Substituierte pyrroloindole
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
DE60032774D1 (de) Spla2 inhibitoren
BR9612000A (pt) Naftil glioxamidas como inibidores de spla; '
ECSP992928A (es) Compuestos triciclicos sustituidos (caso x-12144)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU